|
|
#非洲
日内瓦，2026年9月14日 —— 根据一项关于新型结核病疫苗潜在影响的最新分析显示，预计将于2029年起投入使用的新型结核病疫苗有望在2030年至2050年间拯救多达730万人的生命，并在中低收入国家释放高达1350亿美元的经济效益。这些益处彰显了新型结核病疫苗成为几十年来最具影响力的新型免疫工具的潜力，堪称一项技术突破。\n\n然而，疫苗全球联盟（Gavi）在今天发布的《新型结核病疫苗早期市场塑造路线图》（Early Market Shaping Roadmap for novel TB Vaccines）中警告称，现在必须采取行动，为疫苗的到来做好政府和疫苗制造商层面的准备。根据该路线图，中低收入国家对这些疫苗的需求平均每年可达8600万剂次，其中在早期阶段需求更大，因为高负担国家正寻求扩大保护范围。\n\n在WhatsApp和LinkedIn上获取最新头条新闻\n\n疫苗全球联盟首席执行官Sania Nishtar博士表示：“新型结核病疫苗可能成为下一个重磅免疫工具，然而，只有在我们能够确保为疾病负担最重的国家提供充足、可预测且负担得起的供应时，它们才能发挥其全部潜力。为了帮助各国获得所需数量的剂量，我们现在正开始与合作伙伴合作，为这些疫苗可用时实现及时获取奠定基础。”\n\n2024年，全球有1070万结核病病例，120万人死于结核病。这一负担绝大部分落在中低收入国家身上，其中获得Gavi支持的国家占所有死亡人数的估计77%。目前唯一获得许可的疫苗是卡介苗（BCG），已有100多年的历史，虽然它在保护婴儿和幼儿免受严重形式的疾病感染方面有效，但其保护效果会减弱，这凸显了对新工具的需求。\n\n新疫苗旨在填补这一空白。它们旨在预防青少年和成人的传染性肺结核疾病，将成为抗击结核病领域的一大重要补充。结合其他预防措施，它们可以加速攻克这一全球最致命疾病之一的进程。\n\n随着首批这些具有前景的候选疫苗可能在本十年末获得监管批准，Gavi的路线图识别出了一系列可能阻碍获得许可后快速推广的风险。这些风险包括政策风险（由于证据空白，建议可能仅限于最高风险群体）、可能限制各国采用的风险（如全球和国内融资不足）以及供应风险等。\n\n为了克服这些风险，Gavi提出了三个明确的目标。凭借其在市场塑造和创新融资方面的专业知识，Gavi将致力于实现这些目标，以帮助确保新疫苗以尽可能快和公平的方式送达最需要它们的中低收入国家。这些目标是：
中文导读
跟上WhatsApp上的最新头条| LinkedIn
原文原文 / Original TextGeneva, 14 September 2026 – New tuberculosis (TB) vaccines, which are expected to become available from 2029, could help save up to an estimated 7.3 million lives between 2030 and 2050 1 , unlocking up to US$ 135 billion in economic benefits across low- and middle-income countries, according to new analysis on their potential impact. These benefits highlight the potential for new TB vaccines to become one of the most impactful new immunisation tools in decades, representing a breakthrough tech
Nevertheless, in its Early Market Shaping Roadmap for novel TB Vaccines , published today, Gavi, the Vaccine Alliance (Gavi) warns that action is required now to prepare governments and vaccine manufacturers for the vaccines' arrival. According to the Roadmap, demand for the vaccines among low-income countries and middle-income countries could reach, on average, 86 million vaccination courses per year, with greater demand in the early years as high-burden countries seek to expand protection ac
Keep up with the latest headlines on WhatsApp | LinkedIn
"Novel TB vaccines could be the next blockbuster immunisation tool, however they will only realise their potential if we are able to ensure sufficient, predictable and affordable supply for those countries with the highest disease burden," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. "In order to help countries secure doses in the volumes they need, we are beginning to work with partners now to lay the groundwork for timely access when these vaccines become available."
2024 saw 10.7 million tuberculosis cases and 1.2 million tuberculosis deaths globally. The burden falls overwhelmingly on low- and middle-income countries, with Gavi-supported countries accounting for an estimated 77% of all deaths. The one vaccine currently licensed, the Bacille Calmette-Guérin (BCG) vaccine, is over 100 years old, and while it is effective in protecting infants and young children against severe forms of the disease, its protection wanes, highlighting the need for new tools to
New vaccines aim to fill that gap. Designed to prevent infectious pulmonary TB disease among adolescents and adults, they would be a major addition in the fight against TB. Combined with other prevention measures, they could accelerate progress against one of the world's deadliest diseases.
With the first of these new promising candidate vaccines potentially securing regulatory approval by the end of this decade, Gavi's Roadmap has identified a series of risks that could hold back rapid rollout once licensure is secured. These include policy risks, including the possibility that recommendations could be limited to the highest-risk groups because of gaps in evidence; risks that could limit uptake by countries, such as inadequate global and domestic financing, and supply risks, drive
To overcome these risks, Gavi highlights three well-defined objectives that, drawing on its market-shaping and innovative financing expertise, it will pursue to help ensure new vaccines reach low-income and middle-income countries that need them the most, as fast and equitably as possible. These are:
本文为英文资讯，中文内容由机器翻译生成，仅供参考。详情请阅读文末原文。
—— 资讯转载说明 ——
本文由非洲论坛根据公开信息整理，供中国读者查阅，不代表本站立场。
来源：AllAfrica (https://allafrica.com/)
原文链接：https://allafrica.com/stories/202609150156.html
转载请遵守原发布方版权与引用规定。 |
|
发表于 2026-9-3 22:35:14